Stocksigma LogoStocksigma Logo

Senores Pharmaceuticals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter

Senores Pharmaceuticals confirmed zero deviation in utilizing its ₹500.00 crore IPO proceeds for the quarter ended 30th Sep'26, as per SEBI Regulation 32

Senores Pharmaceuticals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter

Senores Pharmaceuticals Ltd · Others (Uncategorized) · 29 Oct 2026, 10:58 pm

Senores Pharmaceuticals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter Senores Pharmaceuticals confirmed zero deviation in utilizing its ₹500.00 crore IPO proceeds for the quarter ended 30th Sep'26, as per SEBI Regulation 32. Out of the ₹500.00 crore raised, total funds utilized reached ₹418.83 crore. Key deployments include inorganic growth and corporate purposes (₹161.91 crore), debt repayment (₹93.30 crore), and working capital (₹102.74 crore). Fund allocations adhere to objects approved via prospectus and the 3rd Aug'26 postal ballot, with oversight from monitoring agency CARE Ratings.

Original exchange filing (PDF)

More announcements from Senores Pharmaceuticals Ltd

All Senores Pharmaceuticals Ltd announcements